{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:27:05Z","timestamp":1754159225794,"version":"3.41.2"},"reference-count":44,"publisher":"Baishideng Publishing Group Inc.","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Hepatol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Elevated liver enzymes in rheumatoid arthritis (RA) are often attributed to multiple factors including disease activity and treatment-related adverse effects. Tumor necrosis factor inhibitors (TNFi) have shown mixed effects on liver function, with varying safety profiles among agents.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To evaluate the hepatic safety of TNFi therapy\u2014etanercept and adalimumab\u2014in RA patients with elevated liver enzymes.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>A retrospective chart review was conducted for RA patients with elevated liver enzymes receiving TNFi at a single center between January 1, 2019, and September 30, 2024. Out of the patients screened, 9 met the inclusion criteria. Trends in liver enzymes, fibrosis-4 (FIB-4) score, and changes in the Child-Pugh class were analyzed at 1-year and 3-year follow-up periods.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>Among 9 patients (4 on adalimumab, 5 on etanercept), the median age was 56 years [interquartile range (IQR): 49.5\u201364.5 years], 77.8% were female, and the median body mass index was 36.99 kg\/m\u00b2 (IQR: 30.95\u201343.43 kg\/m\u00b2). Median baseline FIB-4 was 1.25 (IQR: 1.02\u20131.65), with no cirrhosis observed at baseline. Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels declined consistently, with significant reductions from baseline to 3 years (P  =  0.003). FIB-4 scores also significantly decreased (P  = 0.003), while albumin, bilirubin, and Child-Pugh class remained stable at the 3-year follow-up. At 3 years, 66.7% achieved RA remission (P  = 0.03).<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>TNFi therapy (adalimumab or etanercept) was associated with significant improvement in liver enzymes and FIB-4 without hepatic decompensation, supporting its safety in our cohort of RA patients with liver involvement. Larger prospective studies are warranted to further validate these findings.<\/jats:p>","DOI":"10.4254\/wjh.v17.i7.108051","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T03:42:06Z","timestamp":1753414926000},"source":"Crossref","is-referenced-by-count":0,"title":["Three-year outcomes of tumor necrosis factor alpha inhibitor therapy in rheumatoid arthritis patients with elevated liver enzymes"],"prefix":"10.4254","volume":"17","author":[{"given":"Shivangini","family":"Duggal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Kattamuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrilekha","family":"Sairam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073848"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S395137"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102227"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101378"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19308"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04262.x"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082199"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14034"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0366-9"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05100.x"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgg.2021.09.009"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3366-2"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.010"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.08.057"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20206"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0253-y"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.12.009"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.025"},{"key":"B19","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u2013"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.024"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.062"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200234"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2010.01.016"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21880"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.112136"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0066-2"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4065\/76.1.84"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626110-00008"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22913"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31798"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.5779"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.4304"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001493"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20560"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001259"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369284"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S393273"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S149832"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1309\/9N346GXX67B6PX5W"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1542962"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2025.10702"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100780"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40139-015-0093-z"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2411-6"}],"container-title":["World Journal of Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i7\/108051.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i7\/108051.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T03:47:01Z","timestamp":1753415221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i7\/108051.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":44,"journal-issue":{"issue":"7"},"alternative-id":["108051"],"URL":"https:\/\/doi.org\/10.4254\/wjh.v17.i7.108051","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,27]]}}}